Clinical Trial Results:
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)
Summary
|
|
EudraCT number |
2009-014373-41 |
Trial protocol |
GB DE FR |
Global end of trial date |
27 Jun 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Sep 2019
|
First version publication date |
21 Sep 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
H135
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN61568166 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Sponsor Ref Number: GN09HM575 | ||
Sponsors
|
|||
Sponsor organisation name |
NHS Greater Glasgow and Clyde
|
||
Sponsor organisation address |
Clinical Research and Development Central Office, Dykebar Hospital, Ward 11, Grahamston Road, Paisley, United Kingdom, PA2 7DE
|
||
Public contact |
Dr Margaret Fegen, NHS Greater Glasgow and Clyde, 0141 314 4172, margaret.fegen@ggc.scot.nhs.uk
|
||
Scientific contact |
Dr Margaret Fegen, NHS Greater Glasgow and Clyde, 0141 314 4172, margaret.fegen@ggc.scot.nhs.uk
|
||
Sponsor organisation name |
University of Glasgow
|
||
Sponsor organisation address |
University Avenue, Glasgow, United Kingdom, G12 8QQ
|
||
Public contact |
Dr Debra Stuart, University of Glasgow, 0141 330 4539, debra.stuart@glasgow.ac.uk
|
||
Scientific contact |
Dr Debra Stuart, University of Glasgow, 0141 330 4539, debra.stuart@glasgow.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Apr 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
14 Dec 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Jun 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
• To provide preliminary evidence that HCQ given in combination with imatinib is more effective than imatinib alone in terms of BCR/ABL levels in CML patients who are in major cytogenetic response with residual BCR/ABL+ cells after at least one year of imatinib treatment. • To determine the safety and tolerability of HCQ given in combination with imatinib in these patients.
|
||
Protection of trial subjects |
The role of the IDMC was to review the accruing trial data and to assess whether there were any safety or efficacy issues that should be brought to participants’ attention or any reasons for the trial not to continue. The IDMC was independent the investigators and was the only body that had access to full accumulating data during the course of the trial. It made recommendations to the UTSC.
|
||
Background therapy |
- | ||
Evidence for comparator |
Imatinib treatment induces CCyR in the majority of CML patients, results in significantly improved survival and is currently front-line treatment for CML. However, most patients continue to have evidence of persistent residual disease detectable by quantitative polymerase chain reaction (Q-PCR) and there are several lines of evidence that residual BCR/ABL+ stem cells persist in CML patients despite Imatinib treatment. Therefore patients require to be treated with Imatinib indefinitely and remain at risk of relapse. Measures to enhance elimination of residual disease are needed to further improve outcomes and effect cure. In preclinical studies CML CD34+ cells were cultured for 6 days in the presence of Imatinib (IM), dasatinib (das), chloroquine (CQ) or combinations in serum free medium supplemented with growth factors prior to long term culture. Results show the recovery of CML stem cells, defined as LTCIC, confirming that combinations of IM or das with CQ are more effective in stem cell eradication than IM or das alone. We have therefore conclusively demonstrated that tyrosine kinase inhibitors, Imatinib, and dasatinib, induce the process of autophagy in CML stem and progenitor cells. In these cells autophagy acts as a survival process allowing the cells to generate energy and remain alive. Chloroquine and HCQ are well known inhibitors of autophagy that are used in laboratory studies, but can also be applied clinically. The combination of the autophagy inhibitor chloroquine with Imatinib results in significantly enhanced eradication of CML primitive progenitors compared to Imatinib or chloroquine alone. HCQ has been used extensively in rheumatology and is well tolerated. These results provide a strong rationale for testing whether addition of HCQ to Imatinib can enhance elimination of residual BCR/ABL+ stem/progenitor cells in Imatinib treated CML patients in MCyR. | ||
Actual start date of recruitment |
01 Apr 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 42
|
||
Country: Number of subjects enrolled |
France: 18
|
||
Country: Number of subjects enrolled |
Germany: 2
|
||
Worldwide total number of subjects |
62
|
||
EEA total number of subjects |
62
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
46
|
||
From 65 to 84 years |
16
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
- | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Pre-randomisation evaluations: • Inclusions/exclusions • Vital signs • Medical and CML history • Physical examination • ECOG PS • 12 lead ECG • Pregnancy test • Visual acuity testing • Haematology (FBC) • Biochemistry (U+E, LFTs) • Bone marrow aspirate for cytogenetics and PD • Peripheral blood PD • Peripheral blood Q-PCR | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Not blinded | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Imatinib alone | |||||||||
Arm description |
Imatinib only. | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Imatinib
|
|||||||||
Investigational medicinal product code |
IM
|
|||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule, hard
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
Patients will receive Imatinib at the dose they were taking prior to trial entry. Imatinib will be obtained from the same commercial source as was used prior to enrolment into the study. Patients should be instructed to take their oral dose of Imatinib at the same time each day. Daily treatment will be withheld only in the case of dose limiting toxicities. The prescribed dose should be administered orally, with a meal and a large glass of water. Patients should keep normal eating habits, however a low-fat meal is recommended avoiding xanthine (e.g. caffeine) or grapefruit containing foods or beverages. A minimum of 1h should be allowed between last drug intake and going to bed. If vomiting occurs, no additional Imatinib should be taken that day in an effort to replace the material that has been vomited. If the patient forgets to take his/her Imatinib dose on scheduled treatment days, then he/she should take it on that same day within 12 hours after the missed dose if possible.
|
|||||||||
Arm title
|
Imatinib plus Hydroxychloroquine | |||||||||
Arm description |
Imatinib and Hydroxychloroquine. Note that Hydroxychloroquine is only given for the first 12 months of treatment. | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Imatinib
|
|||||||||
Investigational medicinal product code |
IM
|
|||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule, hard
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
Patients will receive Imatinib at the dose they were taking prior to trial entry. Imatinib will be obtained from the same commercial source as was used prior to enrolment into the study. Patients should be instructed to take their oral dose of Imatinib at the same time each day. Daily treatment will be withheld only in the case of dose limiting toxicities. The prescribed dose should be administered orally, with a meal and a large glass of water. Patients should keep normal eating habits, however a low-fat meal is recommended avoiding xanthine (e.g. caffeine) or grapefruit containing foods or beverages. A minimum of 1h should be allowed between last drug intake and going to bed. If vomiting occurs, no additional Imatinib should be taken that day in an effort to replace the material that has been vomited. If the patient forgets to take his/her Imatinib dose on scheduled treatment days, then he/she should take it on that same day within 12 hours after the missed dose if possible.
|
|||||||||
Investigational medicinal product name |
Hydroxychloroquine
|
|||||||||
Investigational medicinal product code |
HCQ
|
|||||||||
Other name |
||||||||||
Pharmaceutical forms |
Film-coated tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
Patients will initially receive HCQ at 800mg/day. This will be taken as 400mg twice daily doses approximately 12 hours apart. Patients should be instructed to take their twice-a-day oral doses of HCQ at the same times each day (e.g. 8am and 8pm). Daily treatment will be withheld only in the case of dose limiting toxicities. The prescribed dose should be administered orally, with a meal or a glass of milk. A minimum of 1h should be allowed between last drug intake and going to bed. If the patient forgets to take his/her HCQ dose on scheduled treatment days, then he/she should take it on that same day within 6 hours after the missed dose if possible. After more than 6 hours, that dose should be withheld and the patient should wait to take HCQ at the next scheduled dose either that same day or the following day. Patients should be instructed not to try to make-up the missed dose after 6 hours. The patient should then continue treatment with the original dosing schedule.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Imatinib alone
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Imatinib only. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Imatinib plus Hydroxychloroquine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Imatinib and Hydroxychloroquine. Note that Hydroxychloroquine is only given for the first 12 months of treatment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Imatinib alone
|
||
Reporting group description |
Imatinib only. | ||
Reporting group title |
Imatinib plus Hydroxychloroquine
|
||
Reporting group description |
Imatinib and Hydroxychloroquine. Note that Hydroxychloroquine is only given for the first 12 months of treatment. | ||
Subject analysis set title |
Whole blood HCQ population
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Based on the ITT population IM+HCQ arm, excluding the 6 IM + HCQ patients in the safety run-in period where blood samples were not taken. Patients who have not consented to blood sampling or have withdrawn consent have also been excluded.
|
||
Subject analysis set title |
Imatinib plasma population (IM only)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Based on the ITT population IM only arm, excluding the 6 IM only patients in the safety run-in period where blood samples were not taken. Patients who have not consented to blood sampling or have withdrawn consent have also been excluded.
|
||
Subject analysis set title |
Imatinib plasma population (IM+HCQ)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Based on the ITT population IM+HCQ arm, excluding the 6 IM+HCQ patients in the safety run-in period where blood samples were not taken. Patients who have not consented to blood sampling or have withdrawn consent have also been excluded.
|
|
||||||||||||||||||||||
End point title |
12 month treatment success proportion | |||||||||||||||||||||
End point description |
The proportion of treatment “successes” defined as patients who have >0.5 log reductions in their 12 month PCR level from baseline. Patients who withdraw before the 12 month assessment or who have an increase in their IM dose prior to the assessment will be classified as treatment “failures”.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
12 months post-randomisation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Primary efficacy analysis | |||||||||||||||||||||
Statistical analysis description |
The comparisons between the study arms of 12 month treatment “successes” rates will use Fisher’s exact test. A 95% confidence interval for the difference in proportion will be calculated using method 10 in RG Newcombe.
|
|||||||||||||||||||||
Comparison groups |
Imatinib alone v Imatinib plus Hydroxychloroquine
|
|||||||||||||||||||||
Number of subjects included in analysis |
62
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority [1] | |||||||||||||||||||||
P-value |
= 0.58 [2] | |||||||||||||||||||||
Method |
Fisher exact | |||||||||||||||||||||
Parameter type |
Difference in "success" proportions (%) | |||||||||||||||||||||
Point estimate |
-1.2
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-21.1 | |||||||||||||||||||||
upper limit |
18.4 | |||||||||||||||||||||
Notes [1] - 1-sided hypothesis test, set-up to show 12 month treatment “successes” rate is greater in the IM+HCQ arm than the IM alone arm. [2] - 1-sided. |
|
|||||||||||||||||||||||||
End point title |
24 month treatment success proportion | ||||||||||||||||||||||||
End point description |
The proportion of treatment “successes” defined as patients who have >0.5 log reductions in their 24 month PCR level from baseline. Patients who withdraw before the 24 month assessment or who have an increase in their IM dose prior to the assessment will be classified as treatment “failures”.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
24 months post-randomisation
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
24 month treatment success proportion | ||||||||||||||||||||||||
Statistical analysis description |
The comparisons between the study arms of 24 month treatment “successes” rates will use Fisher’s exact test. A 95% confidence interval for the difference in proportion will be calculated using method 10 in RG Newcombe.
|
||||||||||||||||||||||||
Comparison groups |
Imatinib alone v Imatinib plus Hydroxychloroquine
|
||||||||||||||||||||||||
Number of subjects included in analysis |
62
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority [3] | ||||||||||||||||||||||||
P-value |
= 0.059 [4] | ||||||||||||||||||||||||
Method |
Fisher exact | ||||||||||||||||||||||||
Parameter type |
Difference in "success" proportions (%) | ||||||||||||||||||||||||
Point estimate |
20.8
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-1.5 | ||||||||||||||||||||||||
upper limit |
40.4 | ||||||||||||||||||||||||
Notes [3] - 1-sided hypothesis test, set-up to show 24 month treatment “successes” rate is greater in the IM+HCQ arm than the IM alone arm. [4] - 1-sided |
|
||||||||||||||||||||||
End point title |
12 month molecular response | |||||||||||||||||||||
End point description |
The proportion of patients who achieve Complete or Major Molecular Response at 12 months.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
12 months post-randomisation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
12 month molecular response rates | |||||||||||||||||||||
Statistical analysis description |
The comparisons between the study arms of 12 month molecular response rates will use a Mann-Whitney test. A 95% confidence interval for the difference in proportion will be calculated using method 10 in RG Newcombe.
|
|||||||||||||||||||||
Comparison groups |
Imatinib alone v Imatinib plus Hydroxychloroquine
|
|||||||||||||||||||||
Number of subjects included in analysis |
62
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority [5] | |||||||||||||||||||||
P-value |
= 0.43 [6] | |||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | |||||||||||||||||||||
Parameter type |
Difference in response proportions (%) | |||||||||||||||||||||
Point estimate |
5.2
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-17.1 | |||||||||||||||||||||
upper limit |
27.1 | |||||||||||||||||||||
Notes [5] - 1-sided hypothesis test, set-up to show 12 month molecular response rate is greater in the IM+HCQ arm than the IM alone arm. [6] - 1-sided |
|
||||||||||||||||||||||
End point title |
24 month molecular response | |||||||||||||||||||||
End point description |
The proportion of patients who achieve Complete or Major Molecular Response at 12 months.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
24 months post-randomisation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
24 month molecular response rates | |||||||||||||||||||||
Statistical analysis description |
The comparisons between the study arms of 24 month molecular response rates will use a Mann-Whitney test. A 95% confidence interval for the difference in proportion will be calculated using method 10 in RG Newcombe.
|
|||||||||||||||||||||
Comparison groups |
Imatinib alone v Imatinib plus Hydroxychloroquine
|
|||||||||||||||||||||
Number of subjects included in analysis |
62
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority [7] | |||||||||||||||||||||
P-value |
= 0.33 [8] | |||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | |||||||||||||||||||||
Parameter type |
Difference in response proportions (%) | |||||||||||||||||||||
Point estimate |
8.3
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-13.8 | |||||||||||||||||||||
upper limit |
29.7 | |||||||||||||||||||||
Notes [7] - 1-sided hypothesis test, set-up to show 24 month molecular response rate is greater in the IM+HCQ arm than the IM alone arm. [8] - 1-sided |
|
||||||||||||||||||||||
End point title |
12 month progression rates | |||||||||||||||||||||
End point description |
12 month disease progression proportion.
Note that disease progression (suspected or confirmed) was not recorded for any patient, therefore no analyses were performed.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
12 months post-randomisation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
24 month progression rates | |||||||||||||||||||||
End point description |
24 month disease progression proportion.
Note that disease progression (suspected or confirmed) was not recorded for any patient, therefore no analyses were performed.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
24 months post-randomisation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Imatinib plasma levels (C2D15) | ||||||||||||
End point description |
Change from baseline in Imatinib plasma levels.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Cycle 2, Day 15
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Imatinib plasma levels | ||||||||||||
Statistical analysis description |
Comparison of change from baseline to cycle 2 day 15 in Imatinib plasma levels between the study arms. The difference between the arms is tested using a Mann-Whitney test. An adjustment for multiple comparisons (timepoints) has been made using the false discovery rate (FDR) approach.
Note - patients who have not consented to blood sampling or have withdrawn consent have also been excluded. Blood samples were not taken for the 12 patients (6 IM alone, 6 IM + HCQ) in the safety run-in period.
|
||||||||||||
Comparison groups |
Imatinib plasma population (IM only) v Imatinib plasma population (IM+HCQ)
|
||||||||||||
Number of subjects included in analysis |
39
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.86 [9] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [9] - This is the unadjusted 2-sided p-value. The FDR adjusted 2-sided p-value is 0.93. |
|
|||||||||||||
End point title |
Imatinib plasma levels (C4D1) | ||||||||||||
End point description |
Change from baseline in Imatinib plasma levels.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Cycle 4, Day 1
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Imatinib plasma levels | ||||||||||||
Statistical analysis description |
Comparison of change from baseline to cycle 4 day 1 in Imatinib plasma levels between the study arms. The difference between the arms is tested using a Mann-Whitney test. An adjustment for multiple comparisons (timepoints) has been made using the false discovery rate (FDR) approach.
Note - patients who have not consented to blood sampling or have withdrawn consent have also been excluded. Blood samples were not taken for the 12 patients (6 IM alone, 6 IM + HCQ) in the safety run-in period.
|
||||||||||||
Comparison groups |
Imatinib plasma population (IM only) v Imatinib plasma population (IM+HCQ)
|
||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.32 [10] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [10] - This is the unadjusted 2-sided p-value. The FDR adjusted 2-sided p-value is 0.93. |
|
|||||||||||||
End point title |
Imatinib plasma levels (C7D1) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Cycle 7, Day 1
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Imatinib plasma levels | ||||||||||||
Statistical analysis description |
Comparison of change from baseline to cycle 7 day 1 in Imatinib plasma levels between the study arms. The difference between the arms is tested using a Mann-Whitney test. An adjustment for multiple comparisons (timepoints) has been made using the false discovery rate (FDR) approach.
Note - patients who have not consented to blood sampling or have withdrawn consent have also been excluded. Blood samples were not taken for the 12 patients (6 IM alone, 6 IM + HCQ) in the safety run-in period.
|
||||||||||||
Comparison groups |
Imatinib plasma population (IM only) v Imatinib plasma population (IM+HCQ)
|
||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.93 [11] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [11] - This is the unadjusted 2-sided p-value. The FDR adjusted 2-sided p-value is 0.93. |
|
|||||||||||||
End point title |
Imatinib plasma levels (C10D1) | ||||||||||||
End point description |
Change from baseline in Imatinib plasma levels.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Cycle 10, Day 1
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Imatinib plasma levels | ||||||||||||
Statistical analysis description |
Comparison of change from baseline to cycle 10 day 1 in Imatinib plasma levels between the study arms. The difference between the arms is tested using a Mann-Whitney test. An adjustment for multiple comparisons (timepoints) has been made using the false discovery rate (FDR) approach.
Note - patients who have not consented to blood sampling or have withdrawn consent have also been excluded. Blood samples were not taken for the 12 patients (6 IM alone, 6 IM + HCQ) in the safety run-in period.
|
||||||||||||
Comparison groups |
Imatinib plasma population (IM only) v Imatinib plasma population (IM+HCQ)
|
||||||||||||
Number of subjects included in analysis |
34
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.88 [12] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [12] - This is the unadjusted 2-sided p-value. The FDR adjusted 2-sided p-value is 0.93. |
|
|||||||||||||
End point title |
Imatinib plasma levels (C13D1) | ||||||||||||
End point description |
Change from baseline in Imatinib plasma levels.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Cycle 13, Day 1
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Imatinib plasma levels | ||||||||||||
Statistical analysis description |
Comparison of change from baseline to cycle 13 day 1 in Imatinib plasma levels between the study arms. The difference between the arms is tested using a Mann-Whitney test. An adjustment for multiple comparisons (timepoints) has been made using the false discovery rate (FDR) approach.
Note - patients who have not consented to blood sampling or have withdrawn consent have also been excluded. Blood samples were not taken for the 12 patients (6 IM alone, 6 IM + HCQ) in the safety run-in period.
|
||||||||||||
Comparison groups |
Imatinib plasma population (IM only) v Imatinib plasma population (IM+HCQ)
|
||||||||||||
Number of subjects included in analysis |
34
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.81 [13] | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|||||||||||||
Notes [13] - This is the unadjusted 2-sided p-value. The FDR adjusted 2-sided p-value is 0.93. |
|
|||||||||||
End point title |
Whole blood HCQ levels | ||||||||||
End point description |
Proportion of IM+HCQ patients achieving HCQ concentrations of >2000ng/ml at any point up to 12 months post-randomisation.
Excludes the 6 IM + HCQ patients in the safety run-in period where blood samples were not taken. Patients who have not consented to blood sampling or have withdrawn consent have also been excluded.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Up to 12 months post-randomisation.
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AEs were recorded from the date of randomisation and throughout the study period (24 months post-randomisation) and for at least 30 days after discontinuation of protocol specific medication. All AEs were followed until resolution.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Note - it is not possible to determine the number of occurrences of non-serious AEs from our database. Therefore the number of occurrences of non-serious AEs is assumed to be one per patient.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
IM only safety population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
IM+HCQ safety population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
26 May 2010 |
Amendment Number 1: Amendment to patient information sheet and protocol. Update to the visit schedule for patients on the Imatinib arm of the trial - these patients were not required to come for weekly visits as they had been on a stable dose of Imatinib for >6 months therefore the protocol and patient information sheet were changed to this effect.
Change to the timeline of supportive care for patients with grade 3 nausea, vomiting or diarrhoea from 24 hours to 72 hours made to protocol. |
||
20 Oct 2010 |
Amendment Number 2: For information only, change in the product license number of the IMP (Hydroxychloroquine) and clarification provided regarding the repackaging, labelling and distribution of the IMP. |
||
14 Mar 2011 |
Amendment Number 5: Changes to protocol to incorporate - change of eligibility criteria to include patients that have been on Imatinib treatment for more than 3 years, increase the number of recruiting sites (addition of 2 new sites), reduction in the number of eye exams based on review of the eye toxicity data, and other minor administrative changes to the protocol. |
||
20 Sep 2011 |
Amendment Number 6: Protocol amendment to remove a number of the screening tests which were considered unnecessary and hindering recruitment to the trial and other minor administrative changes. |
||
08 Dec 2011 |
Amendment Number 7: Changes to protocol and provision of further patient information documentation around the visual acuity tests included within the trial. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |